

Metabolic Disorders in Hematologic Malignancies- A Review

Angelo Michele Carella¹,
Teresa Marinelli¹,
Michele Di Pumpo¹,
Ernestina Ponziano²
Angelo Benvenuto¹

Abstract

Metabolic disorders have been observed in patients with hematological malignancies, especially after medical treatment (chemotherapy, corticosteroids, radiation, hormonal agents, and biological response modifiers) as well as following bone marrow and stem cell transplantation. Hyperuricemia is the most common metabolic abnormality; hyperuricaemia less commonly may be associated with hyperkalemia, hyperphosphatemia and hypocalcemia, in the framework of an oncologic emergency that is the Tumor lysis syndrome. Hypercalcemia is relatively common in patients with multiple myeloma and adult T-cell Lymphoma. Cases of Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with hematological malignancies have also been reported. Idiopathic hyperammonemia may occur in oncohematological patients after receiving intensive chemotherapy or following bone marrow transplantation. Moreover, there is evidence that patients with lymphoma, leukemia and multiple myeloma can develop type B lactic acidosis. Non-islet cell tumor hypoglycemia and hyperglycemia are other potential metabolic abnormalities occurring in patients with hematological malignancies.

The pathogenesis of these metabolic disorders is often unclear and several theories have been postulated; possible mechanisms include: increase in neoplastic cell turnover and apoptosis, blast crisis, cytotoxic effects of chemotherapy, tumor secretion of hormones, peptides or cytokines, immune cross-reactivity between malignant and normal tissues, malignancy-induced enzyme dysfunction. Parenteral nutrition, sarcopenia, cachexia, stress, immune deficiency and infections could contribute. Some pathological conditions, such as diabetes mellitus, renal failure, chronic obstructive pulmonary disease, cardiovascular dysfunction, liver disease and other disorders, may predispose oncohematological patients to develop metabolic abnormalities; on the other hand the occurrence of hematological malignancies can worsen pre-existing dysmetabolic conditions, that increase the outcomes of these patients.

Although successful treatment of the underlying tumor often improves metabolic disorders, these conditions often worsen prognosis and are associated with poor survival; thus it is important to consider early detection and effective treatment.

Keywords: Hematologic malignancies, metabolic disorders

1 Internal Medicine Department, T. Masselli-Mascia Hospital - San Severo (Foggia), Italy

2 Department of Clinical Pathology II Laboratory of Analysis, "OO.RR." Hospital - Foggia, Italy

Corresponding Author:

Angelo Michele Carella

✉ mic.carella@virgilio.it

Internal Medicine Department, T. Masselli-Mascia Hospital - San Severo (Foggia), Italy,

Tel: 0882200478

Introduction

Metabolic disorders have been observed in patients with

hematological malignancies, especially after medical treatment (chemotherapy, corticosteroids, radiation, hormonal agents, and

biological response modifiers) as well as following bone marrow and stem cell transplantation [1-4]. During the past several years, medical advances have not only improved the understanding of pathogenetic mechanisms of these metabolic abnormalities but have also enhanced the diagnosis and treatment of these disorders. Moreover, as patients with hematological malignancies live longer, and as diagnostic methods improve, the incidence of these metabolic complications is expected to increase [1,2].

The aim of this review is to focus on diagnosis, potential mechanisms, and treatments of a wide variety of metabolic alterations associated with hematological malignancies.

Material and Methods

A review of literature has been carried out *via* PubMed, using the search terms hematologic malignancies in conjunction with metabolic disorders. Searches were not limited by language or human subjects. All the found items, from August 2010 to August 2015) were analysed. Additional articles were selected from the bibliographies of the quoted references.

Results

151 items were obtained: 16 cases reports, 18 clinical trials, 10 multicenter studies (5 comparative studies, 3 evaluation studies, 3 observational studies), 52 reviews (8 s, 2 editorial comment, 2 m; the remaining items were prevalently small or short-term studies, research supports or other publication types. Hyperuricemia is found to be the most common metabolic abnormality in patients with hematological malignancies; less commonly it may be associated with hyperkalemia, hyperphosphatemia and hypocalcemia in a framework of Tumor lysis syndrome. Hypercalcemia, hypoglycemia and hyperglycemia are relatively common. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH), Idiopathic hyperammonemia and Type B lactic acidosis are less frequently reported.

Discussion

Metabolic alterations are possible complications in oncohematological patients and are typically detected after hematological malignancies diagnosis. However, in some instances these alterations are manifest before tumor diagnosis; then the development of these disorders does not necessarily correlate with cancer stage. The pathogenesis of these metabolic disorders is often unclear and several theories have been postulated; possible mechanisms include: increase in neoplastic cell turnover and apoptosis, blast crisis, cytotoxic effects of chemotherapy, tumor secretion of hormones, peptides or cytokines, immune cross-reactivity between malignant and normal tissues, malignancy-induced enzyme dysfunction [1,5]. Long-term parenteral nutrition, sarcopenia, cachexia, advanced age, stress, immune deficiency and infections could contribute as predisposing factors [6-11]. Moreover, pre-existing comorbidities such as diabetes mellitus, renal failure, chronic obstructive pulmonary disease, cardiovascular dysfunction, liver disease and other disorders, may predispose oncohematological patients to develop metabolic abnormalities; on the other hand the occurrence of hematological malignancies can worsen pre-

existing dysmetabolic conditions, that increase the outcomes of these patients [12-19].

Although several metabolic disorders arise during chemotherapy or following stem cell transplantation, in many cases successful treatment of the underlying malignancy often improves metabolic disorders. Nevertheless these conditions worsen prognosis and are associated with poor survival, thus effective diagnosis and treatment of metabolic disorders may substantially improve overall clinical outcomes; for this reason it is important to consider early diagnosis and prompt treatment [1,2,5].

Hyperuricemia and tumor lysis syndrome

Hyperuricemia is a common metabolic disorder in patients with hematological malignant diseases. **Uric acid is the final oxidation product of purine metabolism** and increments in its plasma level can be realized in these patients by increase in neoplastic cell turnover and apoptosis, blast crisis and breakdown of malignant cells following chemotherapy, as well as it can be caused by an insufficient urinary excretion [20-22]. Less commonly, as a direct consequence of neoplastic disruption intracellular ions, nucleic acids, proteins and their metabolites are released into the plasma causing the framework of the Tumor lysis syndrome (TLS). Characteristic metabolic abnormalities of this oncologic emergency are hyperuricaemia (> 8 mg/dL), hyperkalemia (> 6 mEq/dL), hyperphosphatemia (> 4,5 mg/dL) and hypocalcemia (< 7 mg/dL) [23]. In more serious cases, large amounts of intracellular contents are released so abrupt that the normal homeostatic mechanisms are rapidly overwhelmed and TLS leads to acute renal failure and other complications as seizures, arrhythmias and sudden death [24,25]. TLS is observed most frequently in patients with Acute lymphoblastic leukemia, high-grade lymphomas and Burkitt's lymphoma, although it may also occur in other hematologic malignancies commonly after the initiation of chemotherapy; rarely, TLS can arise spontaneously in oncohematological patients prior to the onset of chemotherapy [26,27]. TLS is a potentially life-threatening metabolic disorder and the identification of patients at risk is essential. Vigorous hydration and antihyperuricemic therapy, at least 2-3 days before the initiation of cytotoxic therapy, remain the cornerstones of TLS prevention. The treatment involves intravenous hydration with approximately 3 L/m²/day and correction of acid-base imbalances; hyperkalemia, hyperphosphatemia and hypocalcemia should be treated expediently according to standard measures [24]. Hyperuricaemia should be treated with Allopurinol, that prevents new uric acid formation by inhibiting xanthine oxidase, or with Rasburicase, a recombinant urate oxidase, that converts pre-existing uric acid to allantoin [22,28,29]. Urinary alkalization is no longer recommended and remains controversial and the role of loop diuretics is not based on solid data, thus it should be approached on an individual basis in patients at increased risk of fluid overload. Patients who have significant acute uremia, fluid overload or severe electrolyte abnormalities, should start hemodialysis as soon as possible; continuous vital signs monitoring is necessary [24].

Hypercalcemia

Multiple myeloma and adult T-cell leukemia/lymphoma are

hematological malignant diseases commonly associated with hypercalcemia [1,30]. Three main mechanisms can be responsible for hypercalcemia in these patients: osteolytic metastases with local release of cytokines, including osteoclast activating factors, tumor secretion of parathyroid hormone-related protein (PTHrP), and tumor production of 1,25-dihydroxyvitamin D (calcitriol) or cytokines such as tumor necrosis factor (TNF), Interleukin 1 (IL-1) and Transforming growth factor alpha (TGF- α). Frequent clinical manifestations of malignancy related hypercalcemia are: nausea, vomiting, ileus, anorexia, dehydration, renal failure, muscle weakness, psychosis, lethargy, coma, and cardiac abnormalities as short QT interval and atrial or ventricular arrhythmia. Thus hypercalcemia may become a life threatening metabolic disorder in oncohematological patients [31,32].

The optimal approach to hypercalcemia related to hematological malignant diseases is to treat the underlying tumor; nevertheless, fluid intravenous hydration with normal saline should be the initial treatment. The hydro-saline replenishment corrects the dehydration and increases the glomerular filtration rate. Although loop diuretics inhibit renal calcium reabsorption, these agents should not be routinely used for all hypercalcemic patients in order not to deteriorate the dehydration; these drugs may be added after adequate fluid replenishment. Intravenous Bisphosphonates are generally established as first-line therapy after volume expansion; these agents have been widely used because of inhibitory effect of bone resorption mediated by osteoclasts. Calcitonin, that inhibits bone resorption and increases the renal calcium excretion, is a useful adjunctive initial therapy. The hypocalcaemic effect of calcitonin appears rapidly but it is often partial and temporary [33]. Of late there is growing interest in the use of Denosumab, a monoclonal antibody against the receptor activator of nuclear factor- κ B ligand (RANKL), in patients with bone metastases. The efficacy of Denosumab for treating malignant hypercalcaemia is currently being evaluated in clinical trials [34,35].

Hypoglycemia

There are evidences that in patients with multiple myeloma, non-Hodgkin's lymphoma and Hodgkin's disease can occur hypoglycemia. Production and release of insulin-like substances by cancer cells is the most recognized pathogenetic mechanisms to explain hypoglycemia in these patients. Tumor cell overproduction of Insulin-like Growth Factor-2 (IGF-2), or its high-molecular-weight precursor (big IGF2), has been proven in some hematological malignant diseases, in association with consequent reduction in the blood glucose level [36-39]. Tumor oversecretion of IGF-2, or big IGF-2, is the main etiologic factor responsible for a specific clinical entity, known as Non-islet-cell tumor hypoglycemia (NICTH), that typically affects elderly patients with advanced cancer [40]. Other pathogenetic mechanisms for hypoglycemia are cancer production of autoantibodies to insulin or its receptor, Insulin-like Growth Factor-1 (IGF-1) tumor secretion and, more rarely, secretion of glucagon-like peptide-1 (GLP-1) or ectopic insulin release. In oncohematological patients, hypoglycemia may also be due to increased glucose consumption by the tumor mass and its metastases, as well as in those with massive liver infiltration [36,41-45]. Iatrogenic hypoglycemia

has been also reported in patients treated with rituximab [46], tyrosine kinase inhibitors [47] and oral purine analogues [48], as well as in those receiving trimethoprim/sulfamethoxazole [49] and levofloxacin [50]. The exact mechanism of chemotherapy-induced hypoglycemia is not clear, while in antibiotic-associated hypoglycemia it has been suggested a sulfonyleurea-like effect [49]. In non-diabetic subjects hypoglycemia is usually diagnosed when venous plasma glucose is <55 mg/dl in presence of symptoms, signs, or both consistent with hypoglycemia, with resolution of those after raising plasma glucose concentration. In addition to low serum glucose levels during acute episodes, NICTH is characterized by an elevated molar IGF-2:IGF-1 ratio [44].

In oncohematological patients, the optimal therapeutic approach to hypoglycemia is to treat the underlying malignancy. When it is not feasible, the aim of therapy is to maintain normal blood glucose levels. In acute hypoglycemia parenteral dextrose exerts an immediate effect on blood glucose, while oral glucose administration raises glycemia in 15 to 30 minutes. For recurrent or chronic hypoglycemia long-term management includes intravenous corticosteroids, glucagon and, in selected cases, octreotide, diazoxide or growth hormone [44,45].

Hyperglycemia

Oncohematological patients are at high risk for hyperglycemia because of several reasons such as prolonged glucocorticoid treatment, immune deficiency state and immunosuppressive therapy, iron overload from repeated transfusion, transplant proceedings, frequent infections, cytokines overproduction, total parenteral nutrition, sarcopenia, cachexia, and medical stress [51]. These permanent or intercurrent factors can further worsen a pre-existing insulin resistance in patients who already have type 2 diabetes, as well as these factors can increase insulin requirement in previously normoglycemic patients. In patients with hematological malignant diseases hyperglycemia is associated with poor outcomes including increased risk of infection, comorbidities and organ dysfunction, shorter duration of remission and, in more serious cases, less eligibility for intensive chemotherapy, higher incidence of graft-versus-host disease and increased mortality [51-54]. Plasma hyperosmolality, ketoacidosis and lactic acidosis are potential life-threatening complication of severe untreated hyperglycemia [55-57] that can precipitate or worsen other metabolic disorders in elderly patients with hematological malignancy. Intravenous hydration, correction of electrolyte imbalance and pH alteration, intensive insulin therapy are the first-line treatment of acute severe hyperglycemia [58]. Oral hypoglycemic agents, unless contraindicated, alternatively could also be used to long-term control of chronic mild-moderate hyperglycemia in type 2 patients with hematological malignant diseases [59].

Type B lactic acidosis

Type B lactic acidosis is a rare complication of malignancy, for the first time reported in patients with acute leukaemia by Field et al. [60]; since then, this metabolic disorders has

been described more often in patients with hematological malignant diseases, mainly non-Hodgkin's lymphoma and acute lymphocytic leukemia [61-64]. The exact cause of lactic acidosis in hematological malignancies remains unknown and several theories have been suggested to explain the mechanisms involved in the development of this metabolic disorder in oncohematological patients. A possible mechanisms includes increase in the glycolytic rate in cancer cells, in part due to an aberrant insulin-like growth factor signaling system that induces the overexpression of hexokinase II, the rate-limiting enzyme involved in glycolysis [65]. Moreover, in the tumor cells the avid consumption of glucose through the glycolytic pathway, even in presence of normal oxygen concentrations, causes overproduction of lactate; this metabolic process is known as aerobic glycolysis or Warburg effect [66,67]. This mechanisms could also explain the occurrence of hypoglycemia in patients with type B lactic acidosis, as reported in some cases of non-Hodgkin's lymphoma [37,68,69]. The overproduction of lactate could also be related to deficiency of thiamine that leads to pyruvate accumulation with increase in lactate production. Type B lactic acidosis can also be caused by a decreased hepatic clearance of lactate, so that oncohematological patients with extensive hepatic infiltration are at increased risk of developing this metabolic alteration. At last, the embolization of cancer cells into the microvasculature, causing tissutal hypoperfusion with increase of anaerobic metabolism, could be another possible mechanism of lactic acidosis. Type B lactic acidosis is defined as lactic acid levels above 5 mmol/L and pH less than 7,30 in whole blood [66,70] and it can be a rapidly fatal metabolic complication if not promptly recognized and treated with emergency chemotherapy; therefore the immediate treatment of the underlying malignancy with chemotherapy is the first-line strategy [70]. Other treatment modalities include dialysis, intravenous thiamine supplementation, sodium bicarbonate infusion, and supportive management [66,70]. However the outcome of the majority of patients with type B lactic acidosis may be invariably fatal, suggesting that lactic acidosis may serve as marker of poor prognosis [70].

Idiopathic hyperammonemia

Idiopathic hyperammonemia is characterized by sudden increase in blood ammonia levels with no other obvious etiology, normal liver function tests and in the absence of inborn errors of metabolism or other identifiable causes; therefore Idiopathic hyperammonemia is a diagnosis of exclusion and all other causes needs to be ruled out. This metabolic disorder is clinically characterized by neurological deterioration which mostly results in intractable coma; cerebral edema is common in these patients due to the osmotic effect of intracellular accumulation of glutamine, the major metabolite of ammonia in the brain [71]. Idiopathic hyperammonemia has been reported in some elderly patients with hematological malignant diseases, following intensive chemotherapy as well as following bone marrow and stem cell transplantation [4,72-74]. Several chemotherapeutic agents may be responsible for this metabolic abnormality; cytarabine, daunomycin, cyclophosphamide, vincristine, etoposide, asparaginase, busulfan, and methotrexate are mainly involved; however there is some evidence of correlation

between Idiopathic hyperammonemia and chemotherapy with vinorelbine, topotecan, cisplatin, rituximab, melphalan, and carboplatin]. Cases of Idiopathic hyperammonemia in patients receiving allogeneic or autologous hematopoietic stem cell transplantation are also reported [75-77]. The pathogenesis of idiopathic hyperammonemia is unclear and was hypothesized to be multifactorial. The acute elevations of ammonia and glutamine suggests an acquired urea cycle defect or a more general mitochondrial dysfunction induced by chemotherapeutic agents [71,73,75,77]. Several hypotheses have been proposed including chemotherapy-induced urea cycle enzymes deficiency, as carbamoyl phosphate synthetase 1 or ornithine transcarbamylase or N-acetylglutamate synthase, and inhibition of oxidative phosphorylation complexes I and V in liver tissue. Some malignancy-related conditions, very common in oncohematological patients, as sepsis and infections, particularly with urea-splitting bacteria, gastrointestinal bleeding, hyporexia, total parenteral nutrition, sarcopenia, protein catabolism and catabolic state could also contribute to hyperammonemia [77-81].

Therapeutic aim in patients with idiopathic hyperammonemia is to correct the biochemical abnormalities and ensure adequate nutritional intake; treatment involves compounds that increase the removal of nitrogen waste. Dietary protein restriction, oral lactulose and ammonia-trapping treatment with intravenous and oral nitrogen scavengers, as sodium phenylacetate and sodium benzoate, are usually able to normalize the ammonia levels. In non-responders patients the expanded use of arginine acid might be warranted and in selected cases intermittent hemodialysis may be requested [82,83].

Syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is characterized by hypo-osmotic euvolemic hyponatremia (< 134 mEq/L) and increased urine osmolality (> 100 mOsm/kg); in cancer patients this syndrome arises from tumor cell production of antidiuretic hormone (ADH), also known as arginine vasopressin, and atrial natriuretic peptide [84,85]. SIADH has been reported in patients with large cell anaplastic lymphoma and M4 acute myeloid leukemia [86-88], as well as after stem cells transplantation [89,90] and during high-dose chemotherapy with some agents as cyclophosphamide and vincristine [91,92]. The clinical signs of SIADH vary with the degree and rapidity of onset of hyponatremia, so that the patients can manifest nausea, anorexia, headache, fatigue, muscle cramps, lethargy, seizures, respiratory depression, coma [93]. The optimal therapy for oncohematological SIADH is treatment of the underlying malignancy which can normalize sodium level; other therapeutic options in correcting hyponatremia are fluid restriction (usually <1000 mL/d), intravenous hypertonic saline, adequate salt and protein intake [84,85,93]. Administration of vasopressin V2-receptor antagonists, as Tolvaptan, results in improvement of serum sodium levels. These drugs, which block arginine vasopressin binding to receptors in the renal ducts, act as aquaretic agents increasing the excretion of free water and retaining the sodium [94]. Since 2009 vasopressin receptor

antagonists can be used in many clinical situations resulting in hyponatremia, including congestive heart failure, cirrhosis and SIADH, but efficacy and safety data in cancer patients are lacking. Therefore these agents are generally considered only after failure of fluid restriction and other therapeutic options [95,96].

Conclusion

A wide variety of metabolic alterations can be associated with hematological malignant diseases, increasing poor outcomes of oncohematological patients. Intensive chemotherapy and

proceedings transplantation are often responsible for metabolic disorders, so that clinicians should consider these potential adverse conditions before starting standard intensive treatment protocols in these patients. Moreover some dysmetabolic conditions are potentially life-threatening and could be serious medical emergencies. Although the immediate treatment of the underlying hematological malignancy should result in clearing of the metabolic disturbance, in several cases intensive and specific therapeutic approaches are requested. Prevention and early detection of these metabolic disorders are of crucial importance and could help improve the management of oncohematological patients.

References

1. Flombaum CD (2000) Metabolic emergencies in the cancer patient. *Semin Oncol* 27: 322-334.
2. Leni Z, Parakkal G, Arcaro A (2013) Emerging metabolic targets in the therapy of hematological malignancies. *Biomed Res Int* 2013: 946206.
3. Lee JH, Choi SJ, Lee JH, Kim SE, Seol M, et al. (2005) Severe metabolic abnormalities after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant* 35: 63-69.
4. Tse N, Cederbaum S, Glaspy JA (1991) Hyperammonemia following allogeneic bone marrow transplantation. *Am J Hematol* 38: 140-141.
5. Spinazzé S, Schrijvers D (2006) Metabolic emergencies. *Crit Rev Oncol Hematol* 58: 79-89.
6. Btaiche IF, Khalidi N (2004) Metabolic complications of parenteral nutrition in adults, part 1. *Am J Health Syst Pharm* 61: 1938-1949.
7. Btaiche IF, Khalidi N (2004) Metabolic complications of parenteral nutrition in adults, Part 2. *Am J Health Syst Pharm* 61: 2050-2057.
8. Evans W (1997) Functional and metabolic consequences of sarcopenia. *J Nutr* 127: 998S-1003S.
9. Argilés JM, López-Soriano FJ, Toledo M, Betancourt A, Serpe R, et al. (2011) The cachexia score (CASCO): a new tool for staging cachectic cancer patients. *J Cachexia Sarcopenia Muscle* 2: 87-93.
10. Preiser JC, Ichai C, Orban JC, Groeneveld AB3 (2014) Metabolic response to the stress of critical illness. *Br J Anaesth* 113: 945-954.
11. Willig AL, Overton ET (2014) Metabolic consequences of HIV: pathogenic insights. *Curr HIV/AIDS Rep* 11: 35-44.
12. Palmer BF, Clegg DJ (2015) Electrolyte and Acid-Base Disturbances in Patients with Diabetes Mellitus. *N Engl J Med* 373: 548-559.
13. Bach LA, Hale LJ2 (2015) Insulin-like growth factors and kidney disease. *Am J Kidney Dis* 65: 327-336.
14. Arcopinto M, Cittadini A (2014) Hormonal alterations in heart failure: anabolic impairment in chronic heart failure - diagnostic, prognostic and therapeutic issues. *Front Horm Res* 43: 57-69.
15. Iozzo P (2010) Metabolic toxicity of the heart: insights from molecular imaging. *Nutr Metab Cardiovasc Dis* 20: 147-156.
16. Carlin BW (2012) COPD and associated comorbidities: a review of current diagnosis and treatment. *Postgrad Med* 124: 225-240.
17. Faner R, Cruz T, López-Giraldo A, Agustí A3 (2014) Network medicine, multimorbidity and the lung in the elderly. *Eur Respir J* 44: 775-788.
18. Sheedfar F, Di Biase S, Koonen D, Vinciguerra M (2013) Liver diseases and aging: friends or foes? *Aging Cell* 12: 950-954.
19. Ghouri N, Preiss D, Sattar N (2010) Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. *Hepatology* 52: 1156-1161.
20. Cairo MS (2002) Prevention and treatment of hyperuricemia in hematological malignancies. *Clin Lymphoma* 3 Suppl 1: S26-31.
21. Oka Y, Tashiro H, Sirasaki R, Yamamoto T, Akiyama N, et al. (2014) Hyperuricemia in hematologic malignancies is caused by an insufficient urinary excretion. *Nucleosides Nucleotides Nucleic Acids* 33: 434-438.
22. Tsimberidou AM, Keating MJ (2005) Hyperuricemic syndromes in cancer patients. *Contrib Nephrol* 147: 47-60.
23. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, et al. (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. *Am J Med* 116: 546-554.
24. Mirrahimov AE, Voore P, Khan M, Ali AM1 (2015) Tumor lysis syndrome: A clinical review. *World J Crit Care Med* 4: 130-138.
25. Karagiannis A, Tzorlalis I, Kakafika A, Pateinakis P, Perifanis V, et al. (2005) Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. *Ann Hematol* 84: 343-346.
26. Firwana BM, Hasan R, Hasan N, Alahdab F, Alnahhas I, et al. (2012) Tumor lysis syndrome: a systematic review of case series and case reports. *Postgrad Med* 124: 92-101.
27. Levine AM (2002) Challenges in the management of Burkitt's lymphoma. *Clin Lymphoma* 3 Suppl 1: S19-25.
28. Dinnel J, Moore BL, Skiver BM, Bose P2 (2015) Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy. *Core Evid* 10: 23-38.
29. Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A (2013) Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. *Am J Kidney Dis* 62: 481-492.
30. Stewart AF1 (2005) Clinical practice. Hypercalcemia associated with cancer. *N Engl J Med* 352: 373-379.
31. Rosner MH, Dalkin AC (2012) Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. *Clin J Am Soc Nephrol* 7: 1722-1729.
32. Clines GA (2011) Mechanisms and treatment of hypercalcemia of malignancy. *Curr Opin Endocrinol Diabetes Obes* 18: 339-346.
33. Lumachi F, Brunello A, Roma A, Basso U (2008) Medical treatment of malignancy-associated hypercalcemia. *Curr Med Chem* 15: 415-421.
34. Maier JD, Levine SN (2015) Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy. *J Intensive Care Med* 30: 235-252.
35. Castellano D, Sepulveda JM, García-Escobar I, Rodríguez-Antolín A, Sundlöv A, et al. (2011) The role of RANK-ligand inhibition in cancer: the story of denosumab. *Oncologist* 16: 136-145.
36. Waldron-Lynch F, Inzucchi SE, Menard L, Tai N, Preston-Hurlburt P, et al. (2012) Relapsing and remitting severe hypoglycemia due to a monoclonal anti-insulin antibody heralding a case of multiple myeloma. *J Clin Endocrinol Metab* 97: 4317-4323.
37. Elhomsy GC, Eranki V, Albert SG, Fesler MJ, Parker SM, et al. (2012) "Hyper-warburgism," a cause of asymptomatic hypoglycemia with lactic acidosis in a patient with non-Hodgkin's lymphoma. *J Clin Endocrinol Metab* 97: 4311-4316.
38. Soares-Welch CV, Zeldenrust SR, Conover CA, Grant CS, Service FJ (2003) Hodgkin's lymphoma manifesting with hypoglycemia. *Endocr Pract* 9: 96-97.
39. Snowden JA, Greaves M, Page K (1994) Reversal of diabetes associated with escape of myeloma: evidence for inappropriate IGF-II secretion. *Br J Haematol* 87: 202-204.
40. Nayar MK, Lombard MG, Furlong NJ, McNulty SJ, Hardy KJ, et al. (2006) Diagnosis and management of nonislet cell tumor hypoglycemia: case series and review of the literature. *Endocrinologist* 16: 227-230.
41. Halsall DJ, Mangi M, Soos M, Fahie-Wilson MN, Wark G, et al. (2007) Hypoglycemia due to an insulin binding antibody in a patient with an IgA-kappa myeloma. *J Clin Endocrinol Metab* 92: 2013-2016.

42. Kulkarni A, Zlabek J, Farnen J, Capla R (2006) Recurrent hypoglycemia and hypothermia in a patient with Hodgkin's disease. *Haematologica* 91: ECR50.
43. Nauck MA, Reinecke M, Perren A, Frystyk J, Berishvili G, et al. (2007) Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. *J Clin Endocrinol Metab* 92: 1600-1605.
44. Iglesias P, Díez JJ (2014) Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. *Eur J Endocrinol* 170: R147-157.
45. Bodnar TW, Acevedo MJ, Pietropaolo M (2014) Management of non-islet-cell tumor hypoglycemia: a clinical review. *J Clin Endocrinol Metab* 99: 713-722.
46. Hussain BM, Geetha N, Lali V, Pandey M (2006) Rituximab induced hypoglycemia in non-Hodgkin's lymphoma. *World J Surg Oncol* 4: 89.
47. Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, et al. (2011) Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. *J Oncol Pharm Pract* 17: 197-202.
48. Bay A, Oner AF, Cesur Y, Dogan M, Etlik O, et al. (2006) Symptomatic hypoglycemia: an unusual side effect of oral purine analogues for treatment of ALL. *Pediatr Blood Cancer* 47: 330-331.
49. Nunnari G, Celesia BM, Bellissimo F, Tosto S, La Rocca M, et al. (2010) Trimethoprim-sulfamethoxazole-associated severe hypoglycaemia: a sulfonylurea-like effect. *Eur Rev Med Pharmacol Sci* 14: 1015-1018.
50. Parra-Riffo H, Lemus-Peñalosa J (2012) Severe levofloxacin-induced hypoglycaemia: a case report and literature review. *Nefrologia* 32: 546-547.
51. Healy SJ, Dungan KM (2015) Hyperglycemia in patients with hematologic malignancies. *Curr Diab Rep* 15: 8.
52. Daniel BT1 (2000) Glycemic crises in patients with hematologic malignancies. *Crit Care Nurs Clin North Am* 12: 297-305.
53. Brunello A, Kapoor R, Extermann M (2011) Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. *Am J Clin Oncol* 34: 292-296.
54. Olausson JM, Hammer MJ, Brady V3 (2014) The impact of hyperglycemia on hematopoietic cell transplantation outcomes: an integrative review. *Oncol Nurs Forum* 41: E302-312.
55. Maletkovic J, Drexler A (2013) Diabetic ketoacidosis and hyperglycemic hyperosmolar state. *Endocrinol Metab Clin North Am* 42: 677-695.
56. Pasquel FJ, Umpierrez GE2 (2014) Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. *Diabetes Care* 37: 3124-3131.
57. Cox K, Cocchi MN, Saliccioli JD, Carney E, Howell M, et al. (2012) Prevalence and significance of lactic acidosis in diabetic ketoacidosis. *J Crit Care* 27: 132-137.
58. Beltran G (2014) Diabetic emergencies: new strategies for an old disease. *Emerg Med Pract* 16: 1-19.
59. Brietzke SA (2015) Oral antihyperglycemic treatment options for type 2 diabetes mellitus. *Med Clin North Am* 99: 87-106.
60. de Groot R, Sprenger RA, Imholz AL, Gerding MN (2011) Type B lactic acidosis in solid malignancies. *Neth J Med* 69: 120-123.
61. De Raes EA, Benoit DD, Depuydt PO, Offner F, Nollet J, et al. (2012) Early recognition of malignant lactic acidosis in clinical practice: report on 6 patients with haematological malignancies. *Acta Clin Belg* 67: 347-351.
62. Lee HS, Kim HJ, Choi S, Kim CK, Lee NS, et al. (2010) A case of type B lactic acidosis in acute leukemia. *Yonsei Med J* 51: 460-462.
63. Gardner AJ, Griffiths J (2015) A case of type B lactic acidosis as a complication of chronic myelomonocytic leukaemia: a case report and review of the literature. *J Med Case Rep* 9: 16.
64. Chang H, Shuai X, Ma HB, Liu T (2010) A case report of acute lymphoblastic leukemia complicated by lactic acidosis. *Int J Hematol* 92: 538-541.
65. Hoogwerf D, van Doorn J, Maartense E (2013) The insulin-like growth factor-system in a patient with diffuse large B-cell non-Hodgkin's lymphoma and lactic acidosis. *Ann Clin Biochem* 50: 169-172.
66. Ruiz JP, Singh AK, Hart P (2011) Type B lactic acidosis secondary to malignancy: case report, review of published cases, insights into pathogenesis, and prospects for therapy. *ScientificWorldJournal* 11: 1316-1324.
67. Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg's contributions to current concepts of cancer metabolism. *Nat Rev Cancer* 11: 325-337.
68. Glasheen JJ, Sorensen MD (2005) Burkitt's lymphoma presenting with lactic acidosis and hypoglycemia - a case presentation. *Leuk Lymphoma* 46: 281-283.
69. Diaz J, Antoine J, Azad N (2010) A case of hypoglycemia, lactic acidosis, and hematologic malignancy. *Endocr Pract* 16: 241-243.
70. Claudino WM, Dias A, Tse W, Sharma VR1 (2015) Type B lactic acidosis: a rare but life threatening hematologic emergency. A case illustration and brief review. *Am J Blood Res* 5: 25-29.
71. Nott L, Price TJ, Pittman K, Patterson K, Fletcher J (2007) Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. *Leuk Lymphoma* 48: 1702-1711.
72. Kwan L, Wang C, Levitt L (2002) Hyperammonemic encephalopathy in multiple myeloma. *N Engl J Med* 346: 1674-1675.
73. Fine P, Adler K, Gerstenfeld D (1989) Idiopathic hyperammonemia after high-dose chemotherapy. *Am J Med* 86: 629.
74. Ho AY, Mijovic A, Pagliuca A, Mufti GJ (1997) Idiopathic hyperammonaemia syndrome following allogeneic peripheral blood progenitor cell transplantation (allo-PBPCT). *Bone Marrow Transplant* 20: 1007-1008.
75. Chen YH, Chiou TJ, Hsu YN, Liu CY (2010) Idiopathic hyperammonemia after chemotherapy with vinorelbine, topotecan, and cisplatin in a patient with acute lymphocytic leukemia. *Hematol Oncol Stem Cell Ther* 3: 199-202.
76. Nott L, Price TJ, Pittman K, Patterson K, Young R, et al. (2008) Hyperammonaemic encephalopathy associated with rituximab-containing chemotherapy. *Intern Med J* 38: 800-803.
77. Laemmle A, Hahn D, Hu L3, Rüfenacht V4, Gautschi M5, et al. (2015) Fatal hyperammonemia and carbamoyl phosphate synthetase 1 (CPS1) deficiency following high-dose chemotherapy and autologous hematopoietic stem cell transplantation. *Mol Genet Metab* 114: 438-444.
78. Clay AS, Hainline BE (2007) Hyperammonemia in the ICU. *Chest* 132: 1368-1378.

79. Kaveggia FF, Thompson JS, Schafer EC, Fischer JL, Taylor RJ (1990) Hyperammonemic encephalopathy in urinary diversion with urea-splitting urinary tract infection. *Arch Intern Med* 150: 2389-2392.
80. Olde Damink SW, Dejong CH, Deutz NE, van Berlo CL, Soeters PB (1999) Upper gastrointestinal bleeding: an ammoniagenic and catabolic event due to the total absence of isoleucine in the haemoglobin molecule. *Med Hypotheses* 52: 515-519.
81. Felig DM, Brusilow SW, Boyer JL (1995) Hyperammonemic coma due to parenteral nutrition in a woman with heterozygous ornithine transcarbamylase deficiency. *Gastroenterology* 109: 282-284.
82. Prado FA, Delfino VD, Grion CM3, de Oliveira JA4 (2015) Hyperammonemia in ICU patients: a frequent finding associated with high mortality. *J Hepatol* 62: 1216-1218.
83. Daniotti M, la Marca G, Fiorini P, Filippi L (2011) New developments in the treatment of hyperammonemia: emerging use of arglucic acid. *Int J Gen Med* 4: 21-28.
84. Ellison DH, Berl T (2007) Clinical practice. The syndrome of inappropriate antidiuresis. *N Engl J Med* 356: 2064-2072.
85. Raftopoulos H1 (2007) Diagnosis and management of hyponatremia in cancer patients. *Support Care Cancer* 15: 1341-1347.
86. Akhtar S, Cheesman E, Jude EB (2013) SIADH and partial hypopituitarism in a patient with intravascular large B-cell lymphoma: a rare cause of a common presentation. *BMJ Case Rep* 2013.
87. Zhu CG, Zhang QZ, Zhu M, Zhai QL, Liang XY, et al. (2013) A case report of syndrome of inappropriate antidiuretic hormone secretion with Castleman's disease and lymphoma. *BMC Endocr Disord* 13: 19.
88. Demirkan F, Vural F, Ozsan GH, Ozcan MA, Ozkal S, et al. (2001) Hemophagocytic syndrome associated with inappropriate secretion of antidiuretic hormone in lymphoma and acute myeloblastic leukemia: report of two cases. *Leuk Lymphoma* 42: 1401-1404.
89. Kobayashi R, Iguchi A, Nakajima M, Sato T, Yoshida M, et al. (2004) Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion complicating stem cell transplantation. *Bone Marrow Transplant* 34: 975-979.
90. Wei J, Xiao Y, Yu X, Zhou J, Zhang Y (2010) Early onset of syndrome of inappropriate antidiuretic hormone secretion (SIADH) after allogeneic haematopoietic stem cell transplantation: case report and review of the literature. *J Int Med Res* 38: 705-710.
91. Baker M, Markman M, Niu J3 (2014) Cyclophosphamide-induced severe acute hyponatremic encephalopathy in patients with breast cancer: report of two cases. *Case Rep Oncol* 7: 550-554.
92. Hamdy DA, El-Geed H, El-Salem S, Zaidan M (2012) Posaconazole-Vincristine Coadministration Triggers Seizure in a Young Female Adult: A Case Report. *Case Rep Hematol* 2012: 343742.
93. Gross P (2012) Clinical management of SIADH. *Ther Adv Endocrinol Metab* 3: 61-73.
94. Dubois EA, Rissmann R, Cohen AF (2012) Tolvaptan. *Br J Clin Pharmacol* 73: 9-11.
95. Bhatt PR, McNeely EB, Lin TE3, Adams KF4, Patterson JH5 (2014) Review of Tolvaptan's Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions. *J Clin Med* 3: 1276-1290.
96. Castillo JJ, Vincent M, Justice E (2012) Diagnosis and management of hyponatremia in cancer patients. *Oncologist* 17: 756-765.